Neutrophils in cancer.

Markus I Diehl, Pamela A Basto, Matthew A Abikenari, Ian L Linde, Derick Okwan-Duodu, Edgar G Engleman

Abstract readReview

In one paragraph

Review in Nature reviews. Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Markus I Diehl *Program in Immunology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-5402-2350

Pamela A Basto *Stanford Cancer Institute, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-5446-7963

Matthew A AbikenariDepartment of Neurosurgery, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-5835-5179

Ian L LindePublic Health Sciences Division/Translational Research Program, Fred Hutchinson Cancer Center, Seattle, WA, USA.

Derick Okwan-DuoduProgram in Immunology, Stanford University, Stanford, CA, USA.

Edgar G EnglemanProgram in Immunology, Stanford University, Stanford, CA, USA. edgareng@stanford.edu.ORCID http://orcid.org/0000-0002-2096-9279

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neutrophils, long appreciated for their central role in host defences, have largely pro-tumorigenic effects in cancer owing to their sensitivity to signals in the tumour environment. Cancers regularly co-opt the functions of neutrophils to promote angiogenesis, immunosuppression, tumour growth and metastasis. However, depending on context, many of the same neutrophil-derived factors involved in these processes can mediate tumour cell killing. In this Review, we examine the functions of neutrophils and their impact on cancer, drawing parallels between their roles in cancer and non-cancer contexts, and highlighting their remarkable sensitivity to environmental cues. We call attention to promising strategies for targeting and manipulating neutrophils for the treatment of cancer.

Identifiers

PMID42706341

DOI10.1038/s41467-023-43573-9

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.